Clinical trials: Circulating Tumor Cell;
Metastatic Melanoma
Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques
The main objective of this study is to compare results for the detection of circulating melanoma cells (CMC) using CellSearch versus EPISPOT (EPithelial ImmunoSPOT) techniques between a group of patients with metastatic melanoma…
- Trial name
- NCT01558349
- Where
- 2 sites in France
- Volunteers
- 73 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Bronchial Cancer
Kinetics of Circulating Tumoral Cells in Bronchial Primitive Cancer
The pronostic value of Circulating Tumoral Cells(CTC) 's dosage by the method ISET® (tumoral cell isolation by size) in patients with bronchial cancer was previously demonstrated.
- Trial name
- NCT03328559
- Testing
- ISET® - Isolation by Size of Tumor cells
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Oropharyngeal Squamous Cell Carcinoma, Carcinoma, Squamous Cell
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
The primary goal of this study is to examine whether recurrence of HPV-associated OPSCC can be predicted by two factors: 1) mutations in genes called TRAF3 and CYLD, and 2) measurements of circulating HPV DNA in blood plasma.
- Conditions
- Oropharyngeal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Head and Neck Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma
- Trial name
- NCT04564989
- Where
- 3 sites in United States
- Volunteers
- 220 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastatic Prostate Cancer, CTC
Validation of the Prostate Cancer Assay - Beta+Pivotal
The Prostate Cancer Assay performance of Celsee Diagnostics circulating tumor cell (CTC) analysis system will be validated in patients diagnosed with metastatic prostate cancer.
- Trial name
- VPCA-B+PIV (NCT02742259)
- Testing
- Blood Draw
- Sponsor
- Celsee Diagnostics
Lung Cancer, Relapse/Recurrence
Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial
For patients with lung cancer who have undergone tumor resection, early relapse significantly impacts survival. However, there are currently no reliable screening or imaging tools available to identify patients at risk of early…
- Trial name
- NCT06262386
- Testing
- Cisplatin based chemottherapy
- Where
- Taiwan
- Volunteers
- 358 people
- Sponsor
- Chang Gung Memorial Hospital
Non Small Cell Lung Cancer
Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate whether the combination of neoadjuvant chemotherapy (chemotherapy before surgery) plus ipilimumab for lung cancer increases the number of patients with detectable circulating T cells with…
- Trial name
- TOP1201 IPI (NCT01820754)
- Testing
- Ipilimumab, Paclitaxel, Cisplatin, Carboplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Non-Small Cell Lung Cancer
Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer
Successful treatment of non-small cell lung cancer with radiation therapy requires that the physicians determine exactly where the tumor is in your body and protect your normal tissue.
- Trial name
- NCT00603057
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- University of Michigan Rogel Cancer Center
Lung Cancer, NSCLC
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
The vast majority of patients with stage I (tumors ≥ 4cm), IIA, IIB (and select stage III) NSCLC are managed with upfront surgery, followed by adjuvant chemotherapy.
- Trial name
- NCT04367311
- Testing
- Atezolizumab, Docetaxel, Cisplatin
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nasser Hanna
Urothelial Carcinoma
Circulating Tumor DNA Response In Urothelial Cancer
The purpose of this clinical trial is to evaluate the effectiveness of pembrolizumab monotherapy following 24 weeks of frontline pembrolizumab \& Enfortumab Vedotin (PEV) in patients with metastatic urothelial cancer (mUC).
- Trial name
- NCT07183319
- Testing
- Pembrolizumab & Enfortumab Vedotin (PEV), Pembrolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Oklahoma
Unresectable Metastatic Melanoma
Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System
The goal of this prospective, low-interventional study is to develop and optimize a highly sensitive and specific method for the detection of the BRAF V600E mutation in liquid biopsy samples from patients with unresectable…
- Trial name
- BRAF SENS (NCT07870265)
- Testing
- Novel CRISPR/Cas12a Electrochemical Bioassay, Reference Standard Molecular Diagnostics (NGS and ddPCR), Serial Peripheral Blood Sampling for Liquid Biopsy
- Where
- Czechia
- Volunteers
- 17 people
- Sponsor
- Masaryk Memorial Cancer Institute
Circulating Tumor Cells
Cancer DNA Screening Pilot Study (CANDACE)
The investigators have developed an assay that can sensitively and specifically detect DNA mutations circulating in human plasma that may be indicators of the presence of a solid tumor.
- Trial name
- CANDACE (NCT02808884)
- Testing
- Circulating tumor DNA assay
- Where
- Canada
- Volunteers
- 1,514 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Lung Cancer, Lung Cancer, Nonsmall Cell
Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA
A central challenge in the fight against lung cancers is how to detect disease in a noninvasive manner before it is detectable by imaging methods.
- Conditions
- Lung Cancer, Lung Cancer, Nonsmall Cell, Lung Cancer, Small Cell
- Trial name
- NCT03499678
- Where
- Kazakhstan
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- HKGepitherapeutics
Nodule Solitary Pulmonary, Non-small Cell Lung Cancer
Biomarkers for Risk Stratification in Lung Cancer
This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco…
- Trial name
- NCT03774758
- Testing
- Guardant Health ct-DNA LUNAR assay
- Where
- 3 sites in United States
- Volunteers
- 1,440 people
- Sponsor
- University of California, San Francisco
Non Small Cell Lung Cancer, Complete Surgical Resection
Using ctDNA to Determine Therapies for Lung Cancer
This is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer coming back in people with…
- Conditions
- Non Small Cell Lung Cancer, Complete Surgical Resection, Circulating Tumor DNA
- Trial name
- ctDNA Lung RCT (NCT04966663)
- Testing
- Nivolumab, Pemetrexed, Gemcitabine
- Where
- Canada
- Volunteers
- 66 people
- Sponsor
- University Health Network, Toronto
Epithelial-Mesenchymal Transition, Circulating Tumor Cells
Aspirin on CTCs of Advanced Breast and Colorectal Cancer
The purpose of this study is to determine whether Aspirin could affect the number and subtype of circulating tumor cells of metastatic breast cancer and colorectal cancer.
- Trial name
- ACABC (NCT02602938)
- Testing
- Aspirin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Provincial People's Hospital
Melanoma (Skin Cancer)
ctDNA for Risk Stratification in Melanoma
This study examines circulating tumor DNA (ctDNA) as a biomarker in patients with primary melanoma, prior to surgical excision. The hypothesis is that ctDNA may be detectable in pre-operative blood samples from patients with…
- Trial name
- NCT07531121
- Where
- Denmark
- Volunteers
- 296 people
- Sponsor
- Herlev and Gentofte Hospital
Neoplastic Cells, Circulating, Pancreatic Cancer
Changes in Biomarkers From Blood Over Time in Patients With Pancreatic Adenocarcinoma
Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality in the United States. The high mortality for these tumors is primarily attributed to the late stage in which most patients are diagnosed, leading to…
- Conditions
- Neoplastic Cells, Circulating, Pancreatic Cancer, Biological Markers
- Trial name
- NCT02974764
- Testing
- No intervention/exposures
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
Neoplastic Cells, Circulating
The Detection of Circulating Tumor Cells (CTCs) in Patients With Renal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment
Circulating tumor cells (CTCs) have the potential to provide a surrogate for'real-time biopsy' of tumor biological activity. Enumeration and molecular characterization of CTCs in renal cancer could play an important role in…
- Trial name
- NCT02450448
- Testing
- Flow cytometry (FCM), RT-PCR
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Breast Cancer
Circulating Tumour Cells Characterization in Breast Cancer Patients
In the current scenario, a reliable liquid biopsy method for predicting outcomes in solid tumors, especially among breast cancer patients, is lacking.
- Trial name
- BioCellPhe (NCT06048835)
- Testing
- Blood sample
- Where
- Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Gastric Cancer
Circulating Tumor Cells (CTCs) in Advanced Gastric Cancer
To assess the predictive value of circulating tumor cells (CTCs) for recurrence of advanced gastric cancer after radical resection.
- Trial name
- NCT01848015
- Testing
- detection of CTCs
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University